Date
Thursday, July 30, 2026
Time
10:50 AM - 11:20 AM (MDT)
Name
Preclinical Testing of an ASO Therapy for Dup15q Syndrome
Description
Matt Judson Submitted:
Agents that normalize UBE3A expression hold promise as Dup15q therapeutics. I will provide an update on our work with Kicho, Inc. to test the tolerability and efficacy in mice of antisense oligonucleotides (ASOs) designed to knock down UBE3A overexpression.
Location Name
Colorado B
Speakers
Moderator(s)
Becky Burdine, Dylan Ritter
Session Type
Presentation